Danaher Corporation $DHR Shares Acquired by Adirondack Trust Co.

Adirondack Trust Co. lifted its stake in Danaher Corporation (NYSE:DHR) by 536.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,963 shares of the conglomerate’s stock after purchasing an additional 11,768 shares during the quarter. Danaher accounts for 1.1% of Adirondack Trust Co.’s portfolio, making the stock its 26th largest position. Adirondack Trust Co.’s holdings in Danaher were worth $3,094,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. Main Street Group LTD acquired a new position in Danaher in the 1st quarter valued at approximately $25,000. N.E.W. Advisory Services LLC purchased a new stake in Danaher in the 2nd quarter worth approximately $25,000. Marquette Asset Management LLC lifted its position in Danaher by 192.1% in the 3rd quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock worth $25,000 after buying an additional 73 shares in the last quarter. Evolution Wealth Management Inc. boosted its stake in shares of Danaher by 208.0% during the 1st quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock valued at $29,000 after buying an additional 104 shares during the period. Finally, Field & Main Bank acquired a new stake in shares of Danaher during the 2nd quarter valued at $29,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher News Summary

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced a collaboration combining Danaher’s scientific instruments, laboratory workflows, automation technologies and data with NVIDIA’s accelerated computing and AI capabilities. The companies aim to advance autonomous science and speed up research, potentially creating new growth opportunities in life-science tools. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is reportedly preparing to launch its first AI-powered autonomous laboratory, expected to operate at commercial scale in early 2027. The initiative could support demand for Danaher’s instruments, software and laboratory automation offerings as AI adoption expands. How to Invest in AI Drug Discovery
• Positive Sentiment: Zacks said Danaher has two indicators associated with a potential earnings beat ahead of its upcoming report. A stronger-than-expected result could reinforce investor confidence following the company’s previous quarterly beat on revenue and earnings. Danaher Earnings Expected to Grow
• Positive Sentiment: Morgan Stanley maintained its $240 price target for DHR, signaling continued confidence in the stock’s outlook and leaving room for further appreciation based on the referenced trading level. Morgan Stanley Keeps $240 Target for Danaher
• Neutral Sentiment: Danaher appointed Daniel L. Comas and Robert Hershberg to its board, expanding it to 13 members. The appointments may strengthen governance and industry expertise but are unlikely to materially affect near-term trading. Danaher Announces Board Appointments

Analyst Upgrades and Downgrades

DHR has been the topic of several research analyst reports. Evercore restated an “outperform” rating and set a $230.00 price target on shares of Danaher in a report on Monday, July 6th. The Goldman Sachs Group increased their price objective on Danaher from $210.00 to $250.00 and gave the stock a “buy” rating in a report on Monday, September 21st. TD Cowen lifted their price objective on Danaher from $236.00 to $255.00 and gave the company a “buy” rating in a research report on Tuesday. Wells Fargo & Company reduced their price objective on Danaher from $212.00 to $195.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 22nd. Finally, Barclays boosted their target price on Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday, October 7th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher Stock Up 0.6%

DHR traded up $1.44 during midday trading on Wednesday, hitting $224.28. 1,890,805 shares of the company’s stock traded hands, compared to its average volume of 4,448,106. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The company has a market cap of $157.66 billion, a PE ratio of 39.79, a price-to-earnings-growth ratio of 2.78 and a beta of 0.76. The stock’s fifty day simple moving average is $212.41 and its 200-day simple moving average is $195.13. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80.

Danaher (NYSE:DHR) last posted its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, topping the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion during the quarter, compared to the consensus estimate of $6.12 billion. During the same period in the previous year, the firm posted $0.77 earnings per share. The company’s revenue for the quarter was up 5.5% compared to the same quarter last year. As a group, equities analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s payout ratio is presently 28.42%.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.